Abstract: The present disclosure relates to a method for protecting DC line impedance phase based on protection and control coordination, and an application scenario of the method for protecting is a three-terminal flexible DC transmission network. The method uses high controllability of a converter after a fault, injects a characteristic signal at a characteristic frequency, and calculates a phase angle of input impedance to determine a fault interval, which effectively improves protection performance, turns passive to active, and is not affected by nonlinearity of the converter. At the same time, compared with a full-bridge MMC, using a half-bridge MMC does not need to perform fault ride-through first when identifying a fault, and does not need to add additional equipment, it creates fault features and can reliably identify an fault interval; improves protection quickness and at the same time also has better economic benefits.

Abstract: The present invention discloses a class of water soluble taxane derivatives, a method for treating tumor using the same, use thereof as anti-tumor drugs and use thereof in the preparation of anti-tumor drugs. The water soluble taxane derivatives have the general formula (I-1), (I-2) or (I-3): wherein, R1 is H or methyl; R2 is H, methyl or acetyl; R3 is phenyl or OC(CH3)3; X is H, C1-6 alkyl or F; Y is F or C1-6 alkyl substituted with one or more F; n is 1, 2, 3, 4, 5 or 6; W is NR4R5.A or R4 and R5 are each independently H, C1-6 alkyl optionally substituted with phenyl, or C3-6 cycloalkyl; m is 0, 1, 2 or 3; and A is a pharmaceutically acceptable acid.

Abstract: The present invention discloses a class of water soluble taxane derivatives, a method for treating tumor using the same, use thereof as anti-tumor drugs and use thereof in the preparation of anti-tumor drugs. The water soluble taxane derivatives have the general formula (I-1), (I-2) or (I-3): wherein, R1 is H or methyl; R2 is H, methyl or acetyl; R3 is phenyl or OC(CH3)3; X is H, C1-6 alkyl or F; Y is F or C1-6 alkyl substituted with one or more F; n is 1, 2, 3, 4, 5or 6; W is NR4R5.A or and R5 are each independently H, C1-6 alkyl optionally substituted with phenyl, or C3-6 cycloalkyl; m is 0, 1, 2 or 3; and A is a pharmaceutically acceptable acid.